Published in Pharma Law Weekly, June 1st, 2004
By granting each other access to their respective intellectual property, the agreement provides a broader, joint position to attract interested third parties when negotiating mutually relevant development and commercial license agreements. The first clinical indication targeted in this arrangement is rheumatoid arthritis, but the agreement provides both...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.